Our managers will contact you as soon as possible.
INTERCHЕM has released a new drug, an antimicrobial and antiseptic drug for using in gynecology.
1 vaginal tablet contains 10 mg of dequalinium chloride, which has a broad spectrum of antimicrobial activity against various gram-positive and gram-negative bacteria, fungi and protozoan single-celled organisms.
-
The use of 10 mg dequalinium chloride for 6 consecutive days provides effective and safe therapy for various vaginal infections in everyday practice [Werner Mendling. Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch Gynecol Obstet (2016)].
-
The level of recommendations for the use of dequalinium chloride for the treatment of bacterial vaginosis – A [Gilbert GG Donders. Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin. Pharmacother. (2014)].
The drug is used for vaginal infections of bacterial and fungal origin (bacterial vaginosis and candidiasis), trichomoniasis, for sanation before gynecologic interventions and childbirth.
“Flumibact IC” is dispensed without a prescription. For complete information on the preparation, see the instructions for medical use.


Recent publications
InterChem Among the Top 13 Best Educational Projects in Ukraine
InterChem has been recognized among the Top 13 Best Educational Projects initiated by Ukrainian businesses. Within the national project “Investing in Education”, the ...
InterChem at URC 2025: Signing of the Ukraine–EU Memorandum on Critical Medicines
Anatoliy Reder, CEO of InterChem and official representative of the Association of Ukrainian Medicines Manufacturers (AULM), signed a Memorandum of Cooperation between Ukraine ...
Anatoliy Reder, CEO of InterChem, ranked among Ukraine’s Top 50 CEOs
Anatoliy Reder became the winner in the nomination “Leader in Pharmaceutical Research and Innovation” in Ukraine’s national Top 50 CEOs ranking. The list ...
Anatoliy Reder, CEO of InterChem: “We are Ukrainians. We do not work with the enemy.”
According to research by Gradus Research and Deloitte, about 70% of Ukrainians have a negative attitude toward brands that continue operating in Russia. ...